Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
Date:10/2/2008

transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced that it ... on Tuesday, Jan. 27, 2015, after the close of the U.S. ... with the investment community at 2 p.m. PT. Participating in the ... and chief executive officer, and other members of Amgen,s senior management ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Microbiology Testing/Clinical Microbiology Market by Product, Clinical ... 2019" report to their offering. ... techniques for the detection of infectious diseases. The ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
...  Premier Research Group announces the appointment of Susan ... Vice President, Clinical Development. In this position, Dr. ... developing the company,s clinical trial management services provided ... industry knowledge and proven leadership skills will be ...
...  LIQUENT, Inc. the global leader in regulatory information ... LIQUENT,s XEVMPD Educational Series and Data Assessment tool. ... the July 2012 deadline for submitting product information ... LIQUENT,s XEVMPD Educational Series is ...
Cached Medicine Technology:Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development 2LIQUENT Announces XEVMPD Educational Series and Data Assessment Tool 2
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... County Hospital Better Serve Tri-State ... Heightened Productivity and Collaboration, BOCA RATON, Fla., ... Indiana, efficient yet responsive medical care depends on,effective ... boost care levels even more, the facility recently ...
... the incidence of liver cancer continues to grow-- fueled in ... so too does the need for tests to help diagnose ... appearing in the January 15 issue of Clinical Cancer Research ... is more accurate than traditional biomarkers in distinguishing liver cancer ...
... Ltd., (Amex: CPD ) announced today that ... final approval for the Company,s,Abbreviated New Drug Application ... and 5/500 mg,(Glipizide/Metformin HCl)., Glipizide/Metformin HCl is ... and exercise, to improve glycemic control in patients ...
... GREEN BAY, Wis., Jan. 14 Shopko announced plans to ... corner of Broadway and,Dousman Street in downtown Green Bay. The ... that will be the first,major anchor in the 90 million ... is expected to open in fall of 2008., "This ...
... Campaign Challenging U.S. to Close the Gaps ... in Breast Cancer Care, Survival, SACRAMENTO, ... from seven California Affiliates of Susan G. Komen,for the Cure will ... Community Challenge, a nationwide tour to close,the gaps in breast cancer ...
... might also pertain to Vytorin, which contains Zetia, ... The long-awaited results of a trial of Zetia, ... Americans, shows the drug confers no medical benefit ... which artery-clogging plaques formed within vessels almost doubled ...
Cached Medicine News:Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 2Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 3Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 4Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 5Health News:Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer 2Health News:Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R) 2Health News:Shopko Express Coming to Downtown Green Bay 2Health News:California Affiliates of Susan G. Komen for the Cure Convene Celebrities, Breast Cancer Survivors and Activists to Challenge Elected Officials to Strengthen Breast Cancer Services 2Health News:California Affiliates of Susan G. Komen for the Cure Convene Celebrities, Breast Cancer Survivors and Activists to Challenge Elected Officials to Strengthen Breast Cancer Services 3Health News:Cholesterol Drug Zetia Doesn't Cut Heart Attack Risk: Study 2Health News:Cholesterol Drug Zetia Doesn't Cut Heart Attack Risk: Study 3
Vision Testing for Infants and Non-Verbal Patients,Using Preferential Looking....
Adult: Letter Acuity, Astigmatic Clock, Binocular Balance, Supression, Fixation Disparity, Stereopsis...
Multi-Acuity: Letter Acuity, Tumbling E,and Allen Tests....
Coat-A-Count PSA IRMA is an,immunoradiometric assay intended for the,quantitative measurement of,prostate-specific antigen (PSA) in serum,to aid in the management of prostate,cancer patient...
Medicine Products: